Modern pharmacologic approaches allow the relative contribution of each receptor to be quantitatively tuned, mitigating adverse effects while preserving efficacy (Finan et al., 2016)
Theres a lot of research demonstrating allulose health benefits
As a consequence, the true HR would potentially be more in favor of GLP-1 RAs than the HRs observed in this study
Retatrutide appears to have a similar safety profile to other GLP-1 medications: No increased risk of pancreatitis in trials so far No hepatotoxicity signals (liver damage) No cases of ketoacidosis Serious adverse events were rare (2.5% of participants) The trials are ongoing, so we'll learn more about long-term safety
Melanotan1 pharmacologically mimics/enhances this paracrine signal to increase eumelanin and UV resistance
The most commonly reported side effects in Phase 2 trials were gastrointestinal, including nausea, vomiting, diarrhoea, constipation, and decreased appetite